Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosamprenavir Calcium

FDA-approved product (tablet, oral), marketed as Fosamprenavir Calcium, Lexiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fosamprenavir Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05; WHO ATC J05AE07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosamprenavir Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosamprenavir Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

    NCT01252940 · start 2010-11

    Registered record
    Registry ID
    NCT01252940
    Conditions
    HIV-1 Infection
    Interventions
    FTC/RPV/TDF; PI; RTV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2014-10
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionFTC/RPV/TDF; PI; RTV; NRTIs
    PhasePhase 3
    Registry statusCompleted

  • IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

    NCT01232361 · start 2010-10-08

    Registered record
    Registry ID
    NCT01232361
    Conditions
    ADHD; HIV
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-10-08
    Completion
    2016-07
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionADHD; HIV
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

    NCT00935480 · start 2010-10

    Registered record
    Registry ID
    NCT00935480
    Conditions
    HIV Infections
    Interventions
    Isentress®; Celsentri®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10
    Completion
    2014-08-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIsentress®; Celsentri®
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

    NCT01140412 · start 2010-07

    Registered record
    Registry ID
    NCT01140412
    Conditions
    Healthy
    Interventions
    Maraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir; Maraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2010-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir; Maraviroc +2 more
    PhasePhase 1
    Registry statusTerminated

  • Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

    NCT00966329 · start 2009-10

    Registered record
    Registry ID
    NCT00966329
    Conditions
    HIV; HIV Infections
    Interventions
    maraviroc; control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-10
    Completion
    2012-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    Interventionmaraviroc; control group
    PhasePhase 4
    Registry statusCompleted

  • Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

    NCT01010399 · start 2009-09

    Registered record
    Registry ID
    NCT01010399
    Conditions
    Hypertriglyceridemia; HIV Infection
    Interventions
    Lovaza; fosamprenavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia; HIV Infection
    InterventionLovaza; fosamprenavir/ritonavir
    PhasePhase 4
    Registry statusCompleted

  • HIV Treatment and CVD Events

    NCT01054638 · start 2009-03

    Registered record
    Registry ID
    NCT01054638
    Conditions
    HIV Infection; Cardiovascular Disease; Infection, Human Immunodeficiency Virus; Acute Myocardial Infarction
    Interventions
    HAART Treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Cardiovascular Disease; Infection, Human Immunodeficiency Virus; Acute Myocardial Infarction
    InterventionHAART Treatment
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

    NCT00817765 · start 2009-01

    Registered record
    Registry ID
    NCT00817765
    Conditions
    HIV Infection; Fungal Infection
    Interventions
    Posaconazole; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Fungal Infection
    InterventionPosaconazole; Fosamprenavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

    NCT00802074 · start 2008-12

    Registered record
    Registry ID
    NCT00802074
    Conditions
    Healthy
    Interventions
    Raltegravir; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRaltegravir; Fosamprenavir; Ritonavir
    PhaseNot applicable
    Registry statusCompleted

  • An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

    NCT00764465 · start 2008-10

    Registered record
    Registry ID
    NCT00764465
    Conditions
    Healthy
    Interventions
    Maraviroc; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Fosamprenavir; Ritonavir
    PhasePhase 2
    Registry statusCompleted

  • PENTA Fosamprenavir Study

    NCT01077635 · start 2008-10

    Registered record
    Registry ID
    NCT01077635
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-09
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionExposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
    PhaseNot recorded
    Registry statusCompleted

  • Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

    NCT00756730 · start 2008-09

    Registered record
    Registry ID
    NCT00756730
    Conditions
    HIV Infections
    Interventions
    ATV/r; DRV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionATV/r; DRV/r
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

    NCT00884793 · start 2008-09

    Registered record
    Registry ID
    NCT00884793
    Conditions
    HIV Infections
    Interventions
    raltegravir; Study NNRTI; Study PI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-09
    Completion
    2010-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionraltegravir; Study NNRTI; Study PI
    PhaseNot applicable
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

    NCT00727597 · start 2008-07

    Registered record
    Registry ID
    NCT00727597
    Conditions
    Human Immunodeficiency Virus Infections
    Interventions
    Efavirenz 600mg; Boosted Lexiva
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-07
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Infections
    InterventionEfavirenz 600mg; Boosted Lexiva
    PhasePhase 3
    Registry statusCompleted